Nurtec ODT rimegepant

The single biggest commercial risk is first-dose nausea causing permanent abandonment before efficacy tolerance develops; a peer-guided "push through dose 2" intervention could save meaningful retention.

• Nurtec ODT earns transformative loyalty among multi-treatment veterans, with patients describing it as life-changing after decades of failed triptans, but roughly 28% of reviewers report a negative experience driven primarily by severe GI reactions.
• First-dose nausea is the critical abandonment trigger, yet corpus evidence shows side effects often diminish after repeat use, making early peer support at dose 1 a high-value retention lever for patient services teams.
• Insurance prior authorization and a retail price exceeding $1,000 generate the loudest sustained frustration in the corpus, including viral social posts about copay-card workarounds that inadvertently exhaust deductibles.
• An emerging off-label signal around visual aura, post-infusion migraines in autoimmune patients, and suspected weight gain warrants pharmacovigilance monitoring and proactive HCP communication before it becomes a reputation issue.